Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2010 - 2015)
Vanda Pharmaceuticals (VNDA) posted Depreciation & Amortization (CF) of $273000.0 for Q1 2026, down 9.3% sequentially from $301000.0 in Q4 2025, and up 18.18% YoY from $231000.0 in Q1 2025.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2010 - 2015) Analysis & Trends
Vanda Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $273000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 18.18% year-over-year to $273000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 29.19% YoY) and the FY2025 annual result came in at $1.1 million, up 28.06% from the prior year.
- Depreciation & Amortization (CF) retreated to $273000.0 in Q1 2026 per VNDA's latest filing, from $301000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $323000.0 in Q1 2022 and troughed at $200000.0 in Q3 2023.
- A 5-year average of $257000.0 and a median of $267000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) slumped 33.11% in 2023, then surged 39.35% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $284000.0 in 2022, then retreated by 27.82% to $205000.0 in 2023, then grew by 7.8% to $221000.0 in 2024, then surged by 36.2% to $301000.0 in 2025, then retreated by 9.3% to $273000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $273000.0, $301000.0, and $301000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2015 | 157,000.00 |
| Jun 30, 2015 | 123,000.00 |
| Mar 31, 2015 | 140,000.00 |
| Dec 31, 2014 | 134,000.00 |
| Sep 30, 2014 | 132,000.00 |
| Jun 30, 2014 | 139,000.00 |
| Mar 31, 2014 | 125,000.00 |
| Dec 31, 2013 | 111,000.00 |
| Sep 30, 2013 | 109,000.00 |
| Jun 30, 2013 | 105,000.00 |
| Mar 31, 2013 | 107,000.00 |
| Dec 31, 2012 | 105,000.00 |
| Sep 30, 2012 | 104,000.00 |
| Jun 30, 2012 | 93,000.00 |
| Mar 31, 2012 | 331,000.00 |
| Dec 31, 2011 | 185,000.00 |
| Sep 30, 2011 | 146,000.00 |
| Jun 30, 2011 | 61,000.00 |
| Mar 31, 2011 | 77,000.00 |
| Dec 31, 2010 | 78,000.00 |